JP2016517408A - 抗ｉｌ−２３抗体を用いた乾癬の治療方法 - Google Patents

抗ｉｌ−２３抗体を用いた乾癬の治療方法 Download PDF

Info

Publication number
JP2016517408A
JP2016517408A JP2016500381A JP2016500381A JP2016517408A JP 2016517408 A JP2016517408 A JP 2016517408A JP 2016500381 A JP2016500381 A JP 2016500381A JP 2016500381 A JP2016500381 A JP 2016500381A JP 2016517408 A JP2016517408 A JP 2016517408A
Authority
JP
Japan
Prior art keywords
antibody
amg139
months
amount
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016500381A
Other languages
English (en)
Japanese (ja)
Inventor
ギブス，ジョン・ピー
ツジ，ウェイン
パン，ウェイ−チアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016517408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2016517408A publication Critical patent/JP2016517408A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
JP2016500381A 2013-03-15 2014-02-25 抗ｉｌ−２３抗体を用いた乾癬の治療方法 Pending JP2016517408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15
US61/789,777 2013-03-15
PCT/US2014/018293 WO2014149425A1 (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019172758A Division JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法

Publications (1)

Publication Number Publication Date
JP2016517408A true JP2016517408A (ja) 2016-06-16

Family

ID=50336511

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016500381A Pending JP2016517408A (ja) 2013-03-15 2014-02-25 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2019172758A Pending JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2021054632A Pending JP2021102644A (ja) 2013-03-15 2021-03-29 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2022175999A Withdrawn JP2023011815A (ja) 2013-03-15 2022-11-02 抗ｉｌ－２３抗体を用いた乾癬の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019172758A Pending JP2020063237A (ja) 2013-03-15 2019-09-24 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2021054632A Pending JP2021102644A (ja) 2013-03-15 2021-03-29 抗ｉｌ−２３抗体を用いた乾癬の治療方法
JP2022175999A Withdrawn JP2023011815A (ja) 2013-03-15 2022-11-02 抗ｉｌ－２３抗体を用いた乾癬の治療方法

Country Status (17)

Country Link
US (3) US20160060337A1 (https=)
EP (2) EP2968488A1 (https=)
JP (4) JP2016517408A (https=)
KR (1) KR20150128858A (https=)
CN (1) CN105209064A (https=)
AP (1) AP2015008803A0 (https=)
AU (3) AU2014238148A1 (https=)
CA (1) CA2906382A1 (https=)
CL (1) CL2015002723A1 (https=)
CR (1) CR20150572A (https=)
EA (1) EA201591581A1 (https=)
HK (1) HK1219425A1 (https=)
IL (2) IL241342A0 (https=)
PH (2) PH12015502129A1 (https=)
SG (2) SG11201507482UA (https=)
TN (1) TN2015000403A1 (https=)
WO (1) WO2014149425A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530697A (ja) * 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP4039275A1 (en) 2012-05-03 2022-08-10 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
CN107206081A (zh) * 2015-02-04 2017-09-26 勃林格殷格翰国际有限公司 治疗炎性疾病的方法
AU2017241776B2 (en) * 2016-03-29 2024-06-20 Janssen Biotech, Inc. Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody
EP3560956A3 (en) * 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
MX2021005236A (es) * 2018-11-05 2021-06-18 Merck Sharp & Dohme Llc Regimen de dosificacion de anticuerpo anti-tigit para el tratamiento de cancer.
MX2021011328A (es) * 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
US12577297B2 (en) 2019-09-09 2026-03-17 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibody formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056600A1 (en) * 2009-10-26 2011-05-12 Amgen Inc. Human il-23 antigen binding proteins
JP2011515404A (ja) * 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法
JP2013504598A (ja) * 2009-09-14 2013-02-07 アボット・ラボラトリーズ 乾癬を治療するための方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
EP1977007A4 (en) * 2005-12-28 2009-11-11 Centocor Ortho Biotech Inc MARKERS AND METHOD FOR THE ASSESSMENT AND TREATMENT OF PSORIASIS AND RELATED DISEASES
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
EP2426145B1 (en) * 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2010002776A2 (en) 2008-06-30 2010-01-07 Black & Decker Inc. Cord protector for power tools
CA2734919C (en) 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23
MX2013003920A (es) * 2010-10-06 2013-06-03 Abbvie Inc Metodos para el tratamiento de la psoriasis.
PH12013500660B1 (en) * 2010-10-08 2017-10-27 Novartis Ag Methods of treating psoriasis using il-17 antagonists
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011515404A (ja) * 2008-03-18 2011-05-19 アボット・ラボラトリーズ 乾癬を治療するための方法
JP2013504598A (ja) * 2009-09-14 2013-02-07 アボット・ラボラトリーズ 乾癬を治療するための方法
WO2011056600A1 (en) * 2009-10-26 2011-05-12 Amgen Inc. Human il-23 antigen binding proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNOLOGICAL REVIEWS, vol. 226, JPN6017038617, 2008, pages 147 - 159, ISSN: 0004040196 *
IMMUNOLOGY, vol. 135, JPN6017038613, 2011, pages 112 - 124, ISSN: 0004040194 *
JOINT BONE SPINE, vol. 75, JPN6017038614, 2008, pages 517 - 519, ISSN: 0004040195 *
LANCET., vol. Vol.371(9625), JPN6017038611, 2008, pages 1665 - 1674, ISSN: 0003658231 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530697A (ja) * 2018-07-18 2021-11-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子

Also Published As

Publication number Publication date
JP2021102644A (ja) 2021-07-15
US20200277368A1 (en) 2020-09-03
AU2019200206A1 (en) 2019-01-31
EP3689369A1 (en) 2020-08-05
US20220135668A1 (en) 2022-05-05
HK1219425A1 (zh) 2017-04-07
US20160060337A1 (en) 2016-03-03
CR20150572A (es) 2016-04-25
SG11201507482UA (en) 2015-10-29
AU2020270495A1 (en) 2020-12-17
PH12019502700A1 (en) 2020-12-07
CA2906382A1 (en) 2014-09-25
WO2014149425A1 (en) 2014-09-25
CL2015002723A1 (es) 2016-03-28
IL241342A0 (en) 2015-11-30
TN2015000403A1 (en) 2017-01-03
CN105209064A (zh) 2015-12-30
IL275093A (en) 2020-07-30
AP2015008803A0 (en) 2015-10-31
SG10201804954UA (en) 2018-07-30
PH12015502129A1 (en) 2016-01-25
JP2023011815A (ja) 2023-01-24
EA201591581A1 (ru) 2016-01-29
KR20150128858A (ko) 2015-11-18
AU2014238148A1 (en) 2015-10-08
JP2020063237A (ja) 2020-04-23
EP2968488A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US20220135668A1 (en) Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
US20200017581A1 (en) Methods for treating chron's disease using an anti-il23 antibody
RU2679141C2 (ru) Способы лечения эозинофильного эзофагита с помощью ингибитора ил-4р
JP2014503482A (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
US20260108601A1 (en) Method of diagnosis and treatment of rheumatoid arthritis
US20210277105A1 (en) Treating ulcerative colitis with brazikumab
KR20220045039A (ko) 크론병 치료를 위한 브라지쿠맙의 용도
HK40034615A (en) Methods for treating psoriasis using an anti-il-23 antibody
HK40034614A (en) Methods for treating crohn’s disease using an anti-il23 antibody

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190523